Capital Management’s United Therapeutics UTHR Stock Holding History

Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-25,245	Closed	-$3.42M	–	96
2017 Q1	$3.42M	Sell	25,245 -10,460	-29%	-$1.58M	1.06%	38
2016 Q4	$5.12M	Sell	35,705 -7,690	-18%	-$982K	1.71%	28
2016 Q3	$5.12M	Sell	43,395 -985	-2%	-$118K	1.89%	25
2016 Q2	$4.7M	Buy	44,380 +6,755	+18%	+$753K	1.82%	25
2016 Q1	$4.19M	Buy	37,625 +2,475	+7%	+$313K	1.62%	27
2015 Q4	$5.5M	Buy	35,150 +18,305	+109%	+$2.66M	2.09%	21
2015 Q3	$2.21M	Buy	16,845 +350	+2%	+$56.1K	0.89%	38
2015 Q2	$2.87M	Sell	16,495 -930	-5%	-$167K	1%	35
2015 Q1	$3M	Sell	17,425 -1,590	-8%	-$242K	1.02%	33
2014 Q4	$2.46M	Buy	19,015 +14,055	+283%	+$1.81M	0.76%	39
2014 Q3	$638K	Buy	+4,960	New	+$511K	0.21%	52

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Management's UTHR Position: Q2 2017 in Review

Capital Management sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 25,245 shares — an estimated $3.42M sold.

Capital Management first reported a position in UTHR in Q3 2014 and held it in 11 quarters. The position peaked at $5.5M in Q4 2015. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

Capital Management reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
Capital Management sold 25,245 United Therapeutics shares in Q2 2017, an estimated $3.42M.
Capital Management first reported a position in United Therapeutics in Q3 2014 and held it in 11 quarters.
Capital Management's United Therapeutics position peaked at $5.5M in Q4 2015.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Capital Management's 13F filing for Q2 2017, filed 17 Jul 2017.